338 related articles for article (PubMed ID: 28869483)
1. Obinutuzumab Plus Chlorambucil in a Patient with Severe Myasthenia Gravis and Chronic Lymphocytic Leukemia.
Russell A; Yaraskavitch M; Fok D; Chhibber S; Street L; Korngut L
J Neuromuscul Dis; 2017; 4(3):251-257. PubMed ID: 28869483
[TBL] [Abstract][Full Text] [Related]
2. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M
N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022
[TBL] [Abstract][Full Text] [Related]
3. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
Rogers KA; Jones JA
Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
[TBL] [Abstract][Full Text] [Related]
4. Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.
Shah A
Ann Pharmacother; 2014 Oct; 48(10):1356-61. PubMed ID: 25037849
[TBL] [Abstract][Full Text] [Related]
5. Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.
Reda G; Orofino N; Cassin R; Sciumè M; Fattizzo B; Cortelezzi A
Expert Opin Drug Saf; 2016 Jun; 15(6):865-73. PubMed ID: 26967902
[TBL] [Abstract][Full Text] [Related]
6. Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.
Panovská A; Němcová L; Nekvindová L; Špaček M; Šimkovič M; Papajík T; Brejcha M; Lysák D; Zuchnická J; Novák J; Starostka D; Poul H; Vrbacký F; Vodárek P; Urbanová R; Plevová K; Pospíšilová Š; Mašlejová S; Brychtová Y; Koriťáková E; Smolej L; Doubek M
Hematol Oncol; 2020 Oct; 38(4):509-516. PubMed ID: 32400885
[TBL] [Abstract][Full Text] [Related]
7. Role of obinutuzumab in the treatment of chronic lymphocytic leukemia.
Jean GW; Comeau JM
Am J Health Syst Pharm; 2015 Jun; 72(11):933-42. PubMed ID: 25987688
[TBL] [Abstract][Full Text] [Related]
8. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
Seiter K; Mamorska-Dyga A
Clin Interv Aging; 2015; 10():951-61. PubMed ID: 26109852
[TBL] [Abstract][Full Text] [Related]
9. Myasthenia gravis as an unusual non-hematological autoimmune manifestation of a relapsed chronic lymphocytic leukemia - clinical case and review of literature.
Dimitrova S; Efraim M; Micheva I
Eur Rev Med Pharmacol Sci; 2023 Jan; 27(2):649-652. PubMed ID: 36734734
[TBL] [Abstract][Full Text] [Related]
10. Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil.
Tam C; Kuss B; Opat S; Boulos J; Marlton P
Intern Med J; 2017 Jul; 47 Suppl 4():5-10. PubMed ID: 28685928
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with the type II anti-CD20 antibody obinutuzumab.
Klein C; Bacac M; Umana P; Fingerle-Rowson G
Expert Opin Investig Drugs; 2017 Oct; 26(10):1145-1162. PubMed ID: 28845710
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Fischer K; Al-Sawaf O; Bahlo J; Fink AM; Tandon M; Dixon M; Robrecht S; Warburton S; Humphrey K; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Boettcher S; Tausch E; Humerickhouse R; Eichhorst B; Wendtner CM; Langerak AW; Kreuzer KA; Ritgen M; Goede V; Stilgenbauer S; Mobasher M; Hallek M
N Engl J Med; 2019 Jun; 380(23):2225-2236. PubMed ID: 31166681
[TBL] [Abstract][Full Text] [Related]
13. Obinutuzumab for chronic lymphocytic leukemia: promise of the first treatment approved with breakthrough therapy designation.
Kakkar AK; Balakrishnan S
J Oncol Pharm Pract; 2015 Oct; 21(5):358-63. PubMed ID: 24827578
[TBL] [Abstract][Full Text] [Related]
14. Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia.
Bourrier N; Landego I; Bucher O; Squires M; Streu E; Hibbert I; Whiteside T; Gibson SB; Geirnaert M; Johnston JB; Dawe DE; Banerji V
BMC Cancer; 2022 Feb; 22(1):148. PubMed ID: 35123433
[TBL] [Abstract][Full Text] [Related]
15. Obinutuzumab for chronic lymphocytic leukemia.
Rioufol C; Salles G
Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
[TBL] [Abstract][Full Text] [Related]
16. U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.
Lee HZ; Miller BW; Kwitkowski VE; Ricci S; DelValle P; Saber H; Grillo J; Bullock J; Florian J; Mehrotra N; Ko CW; Nie L; Shapiro M; Tolnay M; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
Clin Cancer Res; 2014 Aug; 20(15):3902-7. PubMed ID: 24824310
[TBL] [Abstract][Full Text] [Related]
17. Antibodies Produced by CLL Phenotype B Cells in Patients With Myasthenia Gravis Are Not Directed Against Neuromuscular Endplates.
Ingelfinger F; Kramer M; Lutz M; Widmer CC; Piccoli L; Kreutmair S; Wertheimer T; Woodhall M; Waters P; Sallusto F; Lanzavecchia A; Mundt S; Becher B; Schreiner B
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36754834
[TBL] [Abstract][Full Text] [Related]
18. Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia.
Hoy SM
Drugs; 2015 Feb; 75(3):285-96. PubMed ID: 25586272
[TBL] [Abstract][Full Text] [Related]
19. The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?
Milunović V; Mišura Jakobac K; Mandac Rogulj I; Martinović M; Radić-Krišto D; Ostojić Kolonić S
Expert Rev Hematol; 2020 Jul; 13(7):771-779. PubMed ID: 32579408
[TBL] [Abstract][Full Text] [Related]
20. Obinutuzumab in hematologic malignancies: lessons learned to date.
Illidge T; Klein C; Sehn LH; Davies A; Salles G; Cartron G
Cancer Treat Rev; 2015 Nov; 41(9):784-92. PubMed ID: 26190254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]